Chair Medicinal Cannabis Industry Australia
CEO Cann Group
Peter is an experienced public company senior manager with deep knowledge and expertise in marketing and technology development. Since joining Cann Group in May 2016, Peter has reset the business plan as directed by the board and led the company through a successful initial public offering (IPO) to list on the Australian Securities Exchange (ASX), raising $13.5 million while bringing outstanding institutional and cornerstone investor support. This was followed by a subsequent $70m+ capital raising within the same year to accelerate the company’s expansion program. In a 28-year career at Nufarm Limited (ASX: NUF), Peter held senior management roles in marketing, business development, and information technology and led Nufarm’s new technologies division which involved the licensing and commercial development of several new agribusiness technologies. He has project managed the successful integration of newly acquired businesses and has extensive experience working with regulators in Australia and overseas.
CEO & Executive Director Cronos Australia
Rodney Cocks is an Executive Director and Chief Executive Officer of Cronos Australia. Rodney is a Director of NewSouthern Capital, a private equity firm he co-founded which undertakes business in the real estate, cannabis and digital sectors. Prior to Cronos Australia, he was on the Senior Leadership Team at Linfox and was a Consultant at the Boston Consulting Group. Rodney also served on the Counter Narcotics Team of the British Embassy in Kabul, Afghanistan and with the United Nations in Afghanistan, Sri Lanka, Pakistan and Iraq. He started his career as an Infantry Officer in the Australian Army. Rodney holds a BComm from the University of Melbourne, LLB from the Queensland University of Technology, MBA from the Wharton School, University of Pennsylvania, MPA from the Harvard Kennedy School, Harvard University and is a Graduate of the Australian Institute of Company Directors and the Royal Military College, Duntroon. He is an admitted Lawyer to the Supreme Court of New South Wales and was also a Fellow at Harvard University and the 2005 Victorian Australian of the Year. In 2003 Rodney was awarded a Conspicuous Service Medal for his actions in the aftermath of the 2002 Bali bombings.
Executive Chairman & CEO MedReleaf Australia
Russell co-founded MedReleaf Australia with Nathan Davis in 2016 as a privately owned medicinal cannabis company.
He has 35 years success in pharmacy business ownership, management and innovation combined with experience in a number of other fields including pharmacy wholesaling to an 80 member group of pharmacist proprietors, property development, business mentoring, medical centre management and semi-professional sports coaching as an accredited AFLQ senior coach.
Elisabetta Faenza MAICD
CEO LeafCann Group
Elisabetta is an expert in relationship management, optimising individual, organisational and societal outcomes, facilitating collaboration and fundraising through win-win relationships. As Co-Founder and CEO of LeafCann Group, Elisabetta has driven the organisation’s strategic positioning as an industry leader. With her core team Elisabetta has expertly laid the groundwork for product development, acquiring critical infrastructure, and developing patenting, licensing and certification pathways. This has positioned LeafCann as a future operational centre of excellence for the emergent Medicinal Cannabis sector in Australasia and Europe.
Elisabetta is a Clinical Hypnotherapist and consultant hypnotherapist to medical and allied health practices including; pain management specialists, physiotherapists, and dentists. Elisabetta has extensive experience as a strategic planner and relationship manager for transnationals and NGOs in the health and regenerative agriculture sectors. Her experience in project planning, strategic partnerships and fundraising has allowed her to identify key strategic partners and negotiate joint venture agreements both nationally and internationally.
Ido Kanyon is CEO of leading cannabinoid-based pharmaceutical company AusCann, and has extensive pharmaceutical and medical device business experience across the life-science value chain. This covers a comprehensive range of healthcare technologies and commercial strategies from capsules and inhalers to innovative biologics and digital health solutions. Mr. Kanyon has successfully launched innovative medicines globally, providing more patients with access to cost-effective, high-quality, life-changing treatment options.
Prior to AusCann, Mr. Kanyon held a broad range of executive positions at Teva Pharmaceuticals, a NYSE listed company with FY18 revenues of over US$18 billion. This included key leadership roles in Strategic Portfolio Management, Innovative Medicine Brand Marketing, Generics Pharmaceutical Manufacturing, Medical Device Regulatory Affairs and Quality Assurance.
Mr. Kanyon has also worked within an agricultural research organization, led R&D projects for start-up companies, and repeatedly transitioned academic research into robust class III implantable medical devices.
Mr. Kanyon holds a B.Sc. (Agr.) from The Hebrew University of Jerusalem, Israel, an MBA from IE Business School in Spain and Postgraduate training with McKinsey & Co. He holds a fellowship with the College of Physicians of Philadelphia and participates in advisory boards with several technological incubators, such as the leading US accelerator Dreamit Ventures. He has lived and worked in North America, Europe, Asia, and the Middle East.
Chief Operating Officer, Althea
Patty was previously Director of Business Management at MDGH. In that role, she was responsible for the overall business management of the company including legal, financial, HR and statutory reporting requirements. MDGH is the first Australian not-for-profit company to register a new drug with the US Food and Drug Administration (FDA) and receive an FDA Priority Review Voucher.
Prior to her role at MDGH, Patty worked with Gilead Sciences Australia, preparing patient and health-care professional facing materials for drugs launched in the Australian market.
Patty has previously worked in New York as the Director of International Sales for SLM International Inc.
CEO and Managing Director, Epilepsy Action Australia
Carol’s extensive background spans more than 35 years in the not-for-profit human services sector. She has been at the forefront of the medical cannabis movement in Australia. In her role at Epilepsy Action she has had significant contact with people faced with managing very challenging forms of medication resistant epilepsy, with few or no conventional options left. Carol has seen the changes in people’s lives, including reduction in the severity and frequency of seizures, resulting from use of medicinal cannabis.